Pharmaceutical companies yesterday mounted a robust defence of their anti-depressant drugs following research from the University of Hull claiming new-generation drugs had little impact on most patients.

GlaxoSmithKline said the authors' interpretation was "incorrect" and at odds with the benefits of anti-depressants observed in clinical practice. Eli Lilly, the maker of Prozac, echoed these remarks.